Nano-based formulations of thymoquinone are new approaches for psoriasis treatment: a literature review

Psoriasis, a persistent immune-mediated inflammatory skin condition, affects approximately 2-3% of the global population. Current treatments for psoriasis are fraught with limitations, including adverse effects, high costs, and diminishing efficacy over time. Thymoquinone (TQ), derived from seeds, e...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2024-08, Vol.15, p.1416842
Main Authors: Modarresi Chahardehi, Amir, Ojaghi, Hamid Reza, Motedayyen, Hossein, Arefnezhad, Reza
Format: Article
Language:English
Subjects:
Animals
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - therapeutic use
Benzoquinones - administration & dosage
Benzoquinones - chemistry
Benzoquinones - therapeutic use
Drug Compounding
Humans
Immunology
nano-formulation
nano-thymoquinone
Nanoparticles - chemistry
Nigella sativa - chemistry
psoriasis
Psoriasis - drug therapy
Psoriasis - immunology
thymoquinone
topical therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis, a persistent immune-mediated inflammatory skin condition, affects approximately 2-3% of the global population. Current treatments for psoriasis are fraught with limitations, including adverse effects, high costs, and diminishing efficacy over time. Thymoquinone (TQ), derived from seeds, exhibits promising anti-inflammatory, antioxidant, and immunomodulatory properties that could prove beneficial in managing psoriasis. However, TQ's hydrophobic nature and poor bioavailability have hindered its usefulness as a therapeutic agent. Recent research has strategically addressed these challenges by developing nano-thymoquinone (nano-TQ) formulations to enhance delivery and efficacy in treating psoriasis. Preclinical studies employing mouse models have demonstrated that nano-TQ effectively mitigates inflammation, erythema, scaling, epidermal thickness, and cytokine levels in psoriatic lesions. Various nano-TQ formulations, including nanoemulsions, lipid vesicles, nanostructured lipid carriers, and ethosomes, have been explored to improve solubility, facilitate skin penetration, ensure sustained release, and achieve site-specific targeting. Although clinical trials are currently scarce, the outcomes from and animal models are promising. The potential co-delivery of nano-TQ with other anti-psoriatic agents also presents avenues for further investigation.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1416842